Ehlken B, Stevanovic I, Kaplan S, Dresco I, Granados D, Toussi M
IQVIA Commercial GmbH, Munich, Germany.
Sanofi, Barcelona, España.
Rev Neurol. 2021 Dec 1;73(11):373-382. doi: 10.33588/rn.7311.2021247.
Risk minimisation measures for valproate were implemented in Spain in 2015.
The objective of this study is to assess the effectiveness of valproate risk minimisation measures in Spain intended to decrease the use of valproate as a first-line therapy, and to evaluate the prescribing patterns of valproate in women, including women of childbearing potential, in the pre- and post-implementation risk minimisation measures periods.
The prescribing patterns of valproate in females and women of childbearing potential before and after risk minimisation measures implementation were examined using the longitudinal patient data database, which includes patient information from two panels: primary care physicians and neurologists/psychiatrists. Primary endpoint was the proportion of initial valproate prescriptions with at least one medication related to the valproate indications before the valproate initiation date.
The proportion of incident valproate prescriptions with previous use of medication related to valproate indications was 78.0% (95% CI, 73.9%; 81.5%), and 78.2% (74.5%; 81.4%) in the main pre-and post-implementation periods in the primary care physician panel. The corresponding figures for women of childbearing potential were 79.6% (73.6%; 84.5%) and 75.5% (69.7%; 80.6%), respectively. The incidence rate of pregnancies exposed to valproate (per 1,000 person-years) in women of childbearing potential decreased from 17.4 the entire pre-implementation to 8.5 in the entire post-implementation periods.
After the implementation of risk minimisation measures for valproate in Spain, no meaningful change in prescribing was observed regarding the proportion of valproate initiations preceded by prior medication related to valproate indications. The preventative measures recommended for use of valproate in women of childbearing potential should be considered.
2015年西班牙实施了丙戊酸盐风险最小化措施。
本研究的目的是评估西班牙丙戊酸盐风险最小化措施在减少丙戊酸盐作为一线治疗药物使用方面的有效性,并评估在实施风险最小化措施前后,丙戊酸盐在包括有生育潜力女性在内的女性中的处方模式。
利用纵向患者数据数据库检查了实施风险最小化措施前后丙戊酸盐在女性及有生育潜力女性中的处方模式,该数据库包含来自两个小组的患者信息:初级保健医生和神经科医生/精神科医生。主要终点是在丙戊酸盐开始使用日期之前,初始丙戊酸盐处方中至少有一种与丙戊酸盐适应症相关药物的比例。
在初级保健医生小组中,主要实施前和实施后时期,之前使用过与丙戊酸盐适应症相关药物的丙戊酸盐新处方比例分别为78.0%(95%CI,73.9%;81.5%)和78.2%(74.5%;81.4%)。有生育潜力女性的相应数字分别为79.6%(73.6%;84.5%)和75.5%(69.7%;80.6%)。有生育潜力女性中暴露于丙戊酸盐的妊娠发生率(每1000人年)从实施前整个时期的17.4降至实施后整个时期的8.5。
在西班牙实施丙戊酸盐风险最小化措施后,在丙戊酸盐开始使用前使用过与丙戊酸盐适应症相关药物的比例方面,未观察到处方有有意义的变化。应考虑为有生育潜力女性使用丙戊酸盐推荐的预防措施。